Article Text

Download PDFPDF
Long term fenofibrate did not reduce major coronary events but may reduce total CVD events in type 2 diabetes

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

 Q In patients with type 2 diabetes mellitus, what is the effect of long term fenofibrate therapy on coronary heart disease (CHD) events?

Clinical impact ratings GP/FP/Primary care ★★★★★★☆ IM/Ambulatory care ★★★★★★☆ Geriatrics ★★★★★☆☆


Embedded ImageDesign

randomised placebo-controlled trial (Fenofibrate Intervention and Event Lowering in Diabetes [FIELD]).

Embedded ImageAllocation


Embedded ImageBlinding

blinded (clinicians, patients, and outcome assessors).*

Embedded ImageFollow up period

median 5 years.

Embedded ImageSetting

63 centres in Australia, New Zealand, and Finland.

Embedded ImagePatients

9795 patients 50–75 years of age (mean age 62 y, 63% men) who had a World Health Organization diagnosis of type 2 diabetes, total cholesterol concentration 3–6.5 mmol/l, and a total cholesterol/high density lipoprotein (HDL) cholesterol ratio ⩾4 or a triglyceride concentration of 1–5 mmol/l, with no clear indication for lipid modifying therapy. Exclusion criteria were renal impairment, chronic liver disease, symptomatic gallbladder disease, or occurrence of a cardiovascular disease (CVD) event within 3 months …

View Full Text


  • * See glossary

  • For correspondence: Professor A Keech, University of Sydney, Sydney, New South Wales, Australia. tony{at}

  • Sources of funding: Laboratoires Fournier SA and National Health and Medical Research Council.

Linked Articles

  • Glossary
    BMJ Publishing Group Ltd